Skip to main content
SpringerLink
Log in

The Oncogenomics Handbook

  • Book
  • © 2005

Overview

Editors:
  1. William J. LaRochelle

    1. CuraGen Corporation, New Haven

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

  2. Richard A. Shimkets

    1. CuraGen Corporation, New Haven

    View editor publications

    You can also search for this editor in PubMed   Google Scholar

Part of the book series: Cancer Drug Discovery and Development (CDD&D)

This is a preview of subscription content, log in via an institution to check access.

Access this book

Log in via an institution
eBook USD 169.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Other ways to access

Licence this eBook for your library

Institutional subscriptions

Table of contents (44 chapters)

  1. Front Matter

    Pages i-xvii
    Download chapter PDF

  2. Genomics, Cancer Targets, Transcriptomics, and Gene Expression Analysis

    1. Front Matter

      Pages 1-1
      Download chapter PDF

    2. Genomic Resources for Cancer Biologists

      • Xuefeng Bruce Ling, Gene Cutler, Timothy Hoey
      Pages 3-17

    3. Cancer Drug Target Identification by SAGE, LongSAGE, and Digital Karyotyping

      • Heiko Hermeking
      Pages 19-30

    4. Identification of Novel Cancer Target Antigens Utilizing EST and Genome Sequence Databases

      • Tapan K. Bera, Kristi A. Egland, B. K. Lee, Ira Pastan
      Pages 31-42

    5. Tree-Based Cancer Classification and Diagnosis Using Gene Expression Data

      • Heping Zhang
      Pages 43-51

    6. From FISH to Proteomics

      • Balanehru Subramanian, Alexander Nakeff, Frederick Valeriote
      Pages 53-67

    7. Gene Program Signatures for Papillomavirus E2-Mediated Senescence in Cervical Cancer Cells

      • Sarah S. Williams, Bruce J. Aronow, Susanne I. Wells
      Pages 69-88

  3. Advances in Proteomic and Enzymatic Cancer-Profiling Technologies

    1. Front Matter

      Pages 89-89
      Download chapter PDF

    2. Mass-Spectrometry-Based Proteomics for Cancer Biology

      • Chen Xu, John R. Yates III
      Pages 91-107

    3. Chemical Proteomics in Drug Development

      • Douglas A. Jeffery, Amos Baruch, Matthew Bogyo
      Pages 109-122

    4. Proteomics-Based Anticancer Drug Discovery

      • K. K. Jain
      Pages 123-134

    5. Cancer Metabolic Phenotype

      • John R. Griffiths, Marion Stubbs
      Pages 135-149

    6. Focusing Target Discovery and Validation Through Proteogenomics and Molecular Imaging

      • Lucy A. Carver, Jan E. Schnitzer
      Pages 151-163

  4. Cancer Target Validation: Cellular Approaches

    1. Front Matter

      Pages 165-165
      Download chapter PDF

  5. Cancer Target Validation: Cellular Approaches

    1. RNA Interference

      • Mustapha Diallo, Katja Schmitz, Ute Schepers
      Pages 167-193

    2. Image-Based Assays of Cellular Phenotype for Drug Target Discovery and Validation

      • Kris F. Sachsenmeier, Jonathan A. Terrett
      Pages 195-207

  6. Cancer Target Validation: Cellular Approaches

    1. Targeting Inducible Chemotherapy Resistance Mechanisms in Colon Cancer

      • David Ljungman, James C. Cusack Jr.
      Pages 209-228

    2. Targeting Apoptosis Pathways for Cancer Therapy

      • Bharvin K. R. Patel
      Pages 229-244

  7. Cancer Target Validation: Animal Approaches

    1. Front Matter

      Pages 245-245
      Download chapter PDF
Back to top

Keywords

About this book

An integrated overview of cancer drug discovery and development from the bench to the clinic, showing with broad strokes and representative examples the drug development process as a network of linked components leading from the discovered target to the ultimate therapeutic product. Following a systems biology approach, the authors explain genomic databases and how to discover oncological targets from them, how then to advance from the gene and transcript to the level of protein biochemistry, how next to move from the chemical realm to that of the living cell and, ultimately, pursue animal modeling and clinical development. Emerging cancer therapeutics including Ritux an, Erbitux, Gleevec Herceptin, Avastin, ABX-EGF, Velcade, Kepivance, Iressa, Tarceva, and Zevalin are addressed. Highlights include cancer genomics, pharmacogenomics, transcriptomics, gene expression analysis, proteomic and enzymatic cancer profiling technologies, and cellular and animal approaches to cancer target validation.

Reviews

"...an excellent resource to anyone interested in the field of cancer or cancer research. Its comprehensive overview of different perspectives in oncologic genomics will certainly be beneficial to a wide range of professionals in their ultimate endeavors towards further development of advanced cancer therapies." - Doody's Health Sciences and Book Review Journal

"...provides an integrated overview of cancer drug discovery and development...." - BioTech International

Editors and Affiliations

  • CuraGen Corporation, New Haven

    William J. LaRochelle, Richard A. Shimkets

Bibliographic Information

  • Book Title: The Oncogenomics Handbook

  • Editors: William J. LaRochelle, Richard A. Shimkets

  • Series Title: Cancer Drug Discovery and Development

  • DOI: https://doi.org/10.1385/1592598935

  • Publisher: Humana Totowa, NJ

  • eBook Packages: Medicine, Medicine (R0)

  • Copyright Information: Humana Press 2005

  • Hardcover ISBN: 978-1-58829-425-8Published: 15 April 2005

  • eBook ISBN: 978-1-59259-893-9Published: 09 November 2007

  • Series ISSN: 2196-9906

  • Series E-ISSN: 2196-9914

  • Edition Number: 1

  • Number of Pages: XVII, 750

  • Topics: Oncology

Publish with us

Policies and ethics

Back to top

Search

Navigation